<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>33(1)</volume><submitter>Alcantara R</submitter><pubmed_abstract>&lt;h4>Objectives&lt;/h4>To evaluate the feasibility of contrast-enhanced mammography (CEM)-guided biopsy at Hospital del Mar, a Spanish university hospital.&lt;h4>Methods&lt;/h4>We retrospectively reviewed all consecutive women with a suspicious enhancing finding eligible for CEM-guided biopsy, who were prospectively enrolled in a pre-marketing clinical validation and feasibility study (October 2019 to September 2021). CEM-guided biopsy is a stereotactic-based procedure that, by using intravenous iodinated contrast media administration and dual-energy acquisition, provides localisation of enhancing lesions. All the biopsies were performed using a vacuum-assisted device. We collected procedural characteristics (patient position and type of approach), and histopathological results. Feasibility endpoint</pubmed_abstract><journal>European radiology</journal><pagination>417-428</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9755098</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Contrast-enhanced mammography-guided biopsy: technical feasibility and first outcomes.</pubmed_title><pmcid>PMC9755098</pmcid><pubmed_authors>Iotti V</pubmed_authors><pubmed_authors>Alcantara R</pubmed_authors><pubmed_authors>Pitarch M</pubmed_authors><pubmed_authors>Arenas N</pubmed_authors><pubmed_authors>Posso M</pubmed_authors><pubmed_authors>Besutti G</pubmed_authors><pubmed_authors>Ejarque B</pubmed_authors></additional><is_claimable>false</is_claimable><name>Contrast-enhanced mammography-guided biopsy: technical feasibility and first outcomes.</name><description>&lt;h4>Objectives&lt;/h4>To evaluate the feasibility of contrast-enhanced mammography (CEM)-guided biopsy at Hospital del Mar, a Spanish university hospital.&lt;h4>Methods&lt;/h4>We retrospectively reviewed all consecutive women with a suspicious enhancing finding eligible for CEM-guided biopsy, who were prospectively enrolled in a pre-marketing clinical validation and feasibility study (October 2019 to September 2021). CEM-guided biopsy is a stereotactic-based procedure that, by using intravenous iodinated contrast media administration and dual-energy acquisition, provides localisation of enhancing lesions. All the biopsies were performed using a vacuum-assisted device. We collected procedural characteristics (patient position and type of approach), and histopathological results. Feasibility endpoint</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jan</publication><modification>2026-07-14T15:58:28.585Z</modification><creation>2025-04-06T19:26:38.626Z</creation></dates><accession>S-EPMC9755098</accession><cross_references><pubmed>35895121</pubmed><doi>10.1007/s00330-022-09021-w</doi></cross_references></HashMap>